☆ 4.6 Editorial Material

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

LIVER CANCER (2020)

Journal

LIVER CANCER

Volume 9, Issue 6, Pages 629-639

Publisher

KARGER

DOI: 10.1159/000512170

Keywords

Immune checkpoint inhibitors; Atezolizumab; Bevacizumab; Combination immunotherapy

Categories

Oncology Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma

Valentina Zanuso, Angelo Pirozzi, Rita Balsano, Tiziana Pressiani, Lorenza Rimassa

Summary: Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Immunotherapy combinations have become the standard first-line treatment, improving overall survival and quality of life. However, predictive biomarkers for patient selection and optimal subsequent therapy for treatment failure are still lacking.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2023)

Add to Collection

Review Pharmacology & Pharmacy

Nanomedicine for Combination Urologic Cancer Immunotherapy

Yun Tian, Zhenzhu Liu, Jianbo Wang, Linan Li, Fuli Wang, Zheng Zhu, Xuejian Wang

Summary: Urologic cancers, such as kidney, bladder, and prostate cancer, have a growing incidence and cause a significant number of deaths worldwide. Immunotherapy, including immunological checkpoint blockade, non-specific activation of the immune system, adoptive cell therapy, and tumor vaccine, shows promise but faces challenges in terms of toxicities and response rates. Nanomaterial-based platforms offer solutions by combining nanotechnology with immunotherapy, leading to precision medicine, improved efficacy, and reduced toxicities in urologic cancer treatment.

PHARMACEUTICS (2023)

Add to Collection

Article Oncology

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

Rom Leidner, Kevin Conlon, Douglas G. Mcneel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A. O'Keeffe, Nancy Lewis, George N. Pavlakis, John A. Thompson

Summary: This study investigated the efficacy and safety of NIZ985 as monotherapy and in combination with spartalizumab in the treatment of advanced solid tumors. The results showed that NIZ985 demonstrated antitumor activity and was well tolerated in patients with advanced solid tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Oncology

Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma

Antonio D'Alessio, Antonella Cammarota, Valentina Zanuso, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa

Summary: The combination of atezolizumab plus bevacizumab has become the current standard of care for first-line treatment of unresectable or metastatic HCC, showing superior efficacy. Further research is needed to assess treatment sequencing and subsequent therapies.

EXPERT REVIEW OF ANTICANCER THERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination

Sri Harsha Tella, Anuhya Kommalapati, Amit Mahipal, Zhaohui Jin

Summary: Hepatocellular carcinoma (HCC) is a common and aggressive malignancy. Treatment options depend on disease stage, liver function, and clinical evaluation. Combination of immunotherapy and anti-VEGF therapy has shown better efficacy in first-line treatment of advanced HCC.

BIOMEDICINES (2022)

Add to Collection

Review Oncology

A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy

Yuhei Miyasaka, Hiro Sato, Naoko Okano, Nobuteru Kubo, Hidemasa Kawamura, Tatsuya Ohno

Summary: Lung cancer is a leading cause of cancer-related deaths worldwide. Radiotherapy has achieved significant technical advances and is widely used in the management of lung cancer. The anti-tumor effect of radiotherapy is mainly caused by DNA damage in cancer cells. Additionally, radiotherapy induces anti-tumor immune responses, but also suppresses the immune system. Combining radiotherapy with immunotherapy, particularly immune checkpoint inhibitors, shows promise in overcoming immunosuppressive conditions in lung cancer patients. Particle therapy using protons and carbon ions in combination with immunotherapy is also a promising treatment strategy according to evidence outlined in this review.

CANCERS (2022)

Add to Collection

Review Chemistry, Multidisciplinary

Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights

Jiao-jiao Ni, Zi-zhen Zhang, Ming-jie Ge, Jing-yu Chen, Wei Zhuo

Summary: As a breakthrough strategy for cancer treatment, immunotherapy stimulates the immune system to fight cancer, providing a durable antitumor response. Due to the low response rate and unique toxicity profiles of immunotherapy, combining it with other therapies has gained attention. Immune-based combination therapy has achieved promising results in clinical trials, with FDA approval for certain cancers.

ACTA PHARMACOLOGICA SINICA (2023)

Add to Collection

Letter Immunology

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Nicolas Lambert, Solene Dauby, Dominique Dive, Bernard Sadzot, Pierre Maquet

Summary: Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, but it also resulted in immune reconstitution inflammatory syndrome and life-threatening immune-related adverse events.

EMERGING INFECTIOUS DISEASES (2022)

Add to Collection

Review Nanoscience & Nanotechnology

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors

Jing Qi, Feiyang Jin, Xiaoling Xu, Yongzhong Du

Summary: Cancer immunotherapy aims to enhance immune responses against cancer, with the combination of ICD inducers and immune checkpoint inhibitors showing significant antitumor effects. Nanoparticles can modulate systemic biodistribution and facilitate the clinical translation of immunotherapies.

INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)

Add to Collection

Article Immunology

Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy

Ayo S. Falade, Kerry L. Reynolds, Leyre Zubiri, Vikram Deshpande, Florian J. Fintelmann, Michael Dougan, Meghan J. Mooradian

Summary: Immune checkpoint inhibitors are an important treatment option for tumors, but can lead to immune-related adverse events. This case report presents a patient with widespread metastatic melanoma who developed rapid onset anasarca and transaminitis after treatment with dual anti-PD-1/CTLA-4 therapy. Further investigation revealed celiac disease, which resolved with a gluten-free diet. This case emphasizes the need for a broad differential diagnosis when managing suspected immune-related adverse events.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma

Perla Chami, Youssef Diab, Danny N. Khalil, Hassan Azhari, William R. Jarnagin, Ghassan K. Abou-Alfa, James J. Harding, Joseph Hajj, Jennifer Ma, Maria El Homsi, Marsha Reyngold, Christopher Crane, Carla Hajj

Summary: The liver tumor immune microenvironment plays a crucial role in the development and progression of HCC. While immune checkpoint inhibitors have limited efficacy in HCC, it has been found that radiation therapy can overcome some of these limitations and reshape the liver immune microenvironment. Combining radiation therapy with immune checkpoint inhibitors effectively restores anti-tumor activity.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG

Anne Zaremba, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Claudia Pfoehler, Michael Weichenthal, Patrick Terheyden, Andrea Forschner, Ulrike Leiter, Jens Ulrich, Jochen Utikal, Julia Welzel, Martin Kaatz, Christoffer Gebhardt, Rudolf Herbst, Anca Sindrilaru, Edgar Dippel, Michael Sachse, Frank Meiss, Lucie Heinzerling, Sebastian Haferkamp, Carsten Weishaupt, Harald Loeffler, Sophia Kreft, Klaus Griewank, Elisabeth Livingstone, Dirk Schadendorf, Selma Ugurel, Lisa Zimmer

Summary: This study analyzed the impact of NRAS gene mutations on melanoma patients treated with immune checkpoint inhibitors. The results showed that NRAS mutations were not significantly correlated with patients' survival and treatment response, and had no correlation with the expression of the T-cell immune checkpoint molecule PD-L1.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes

Yukinori Endo, Katie L. Winarski, Md Sanaullah Sajib, Anna Ju, Wen Jin Wu

Summary: Atezolizumab, an immune checkpoint inhibitor targeting PD-L1, may cause liver toxicity by inducing PD-L1-mediated cell death in hepatocytes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Oncology

Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records

Mathilde Beaufils, Vincent Amodru, Manuel Tejeda, Jean Marie Boher, Christophe Zemmour, Brice Chanez, Anne Sophie Chretien, Laurent Gorvel, Gwenaelle Gravis, Damien Bruyat, Roxane Mari, Anne Madroszyk, Thomas Cuny, Anthony Goncalves, Aaron E. Lisberg, Daniel Olive, Louis Tassy, Frederic Castinetti, Philippe Rochigneux

Summary: Data mining analysis showed that immune checkpoint inhibitor (ICI)-induced dysthyroidism (DT) was associated with improved overall survival (OS), and patients with both DT and other immune-related adverse events had even longer OS.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Review Chemistry, Multidisciplinary

Radiotherapy-activated tumor immune microenvironment: Realizing radiotherapy-immunity combination therapy strategies

Haifen Luo, Wen Ma, Qi Chen, Zhen Yang, Yunlu Dai

Summary: Radiotherapy can induce immune responses in the tumor microenvironment, but it can also increase immune suppressor cells, limiting its effectiveness. Nanomedicine can deliver immunoadjuvants to block immune suppression and improve the combination of radiotherapy and immunotherapy.

NANO TODAY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni

Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.

JOURNAL OF HEPATOLOGY (2023)

Add to Collection

Article Oncology

Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety

Philippe Merle, Masatoshi Kudo, Stanimira Krotneva, Kirhan Ozgurdal, Yun Su, Irina Proskorovsky

Summary: This study compared the efficacy and safety of regorafenib and cabozantinib in the second-line treatment of advanced hepatocellular carcinoma. The results showed that regorafenib had a favorable overall survival, lower rates of dose reduction and treatment discontinuation due to adverse events, and lower rates of severe diarrhea and fatigue compared to cabozantinib.

LIVER CANCER (2023)

Add to Collection

Editorial Material Oncology

Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity

Masatoshi Kudo

LIVER CANCER (2023)

Add to Collection

Review Oncology

Imaging Diagnosis of various HCC subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial Intelligence

Yasunori Minami, Naoshi Nishida, Masatoshi Kudo

Summary: This article discusses the imaging characteristics and differential diagnosis of hepatocellular carcinoma and other hypervascular liver lesions. Artificial intelligence in medical imaging analysis shows promise as a decision support tool, but further validation is needed.

LIVER CANCER (2023)

Add to Collection

Review Oncology

Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review

Arndt Vogel, Robin Katie Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa

Summary: A systematic literature review reveals the importance of liver function assessments in predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma. The study supports liver function as a prognostic marker and highlights the value of stratifying patients based on baseline liver function in clinical trials for aHCC.

LIVER CANCER (2023)

Add to Collection

Article Oncology

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stephane Cattan, Yee Chao, Abby B. Siegel, Ivan Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn

Summary: With extended follow-up, pembrolizumab demonstrated continued improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in advanced hepatocellular carcinoma (HCC) patients previously treated with sorafenib. The adverse event profile of pembrolizumab remained consistent with placebo.

LIVER CANCER (2023)

Add to Collection

Article Oncology

Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study

Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L. Chan, Masayuki Kurosaki, Namiki Izumi

Summary: The concept of curative conversion by combining systemic therapy and locoregional therapy in intermediate-stage HCC has not been reported before. This study aimed to show the value of curative conversion in immunotherapy-treated HCC. The results showed that 35% of patients achieved CR through resection, ablation, or super selective TACE.

LIVER CANCER (2023)

Add to Collection

Review Oncology

Advances in Immunotherapy for Hepatocellular Carcinoma

Satoru Hagiwara, Naoshi Nishida, Masatoshi Kudo

Summary: Immunotherapy for hepatocellular carcinoma (HCC) is rapidly advancing, with a focus on analyzing the tumor immune environment and developing custom-made treatments. Understanding the immune environment of HCC is vital for selecting appropriate immune checkpoint inhibitors (ICIs) and managing their side effects. This summary aims to review the progress of immunotherapy in HCC and its implications for future treatment.

CANCERS (2023)

Add to Collection

Article Oncology

Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma

Naoshi Nishida, Tomoko Aoki, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Hiroshi Ida, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Masatoshi Kudo

Summary: Cholangiocarcinoma (CCA) is a resistant cancer, and a majority of CCAs have a non-inflamed tumor phenotype resistant to treatment, including immune checkpoint inhibitors (ICIs). This study aimed to understand the molecular characteristics of non-inflamed CCAs. The genetic/epigenetic status of 36 CCAs was analyzed, and it was found that tumors with alterations in FGFR2 and IDH1/2 had a non-inflamed phenotype. Downregulation of genes involved in antigen presentation and DNA methylation were associated with the non-inflamed phenotype. These findings provide important insights for developing new strategies to treat CCA.

CANCERS (2023)

Add to Collection

Review Medicine, General & Internal

Contrast-Enhanced Harmonic Endoscopic Ultrasound-Guided Puncture for the Patients with Pancreatic Masses

Yasuo Otsuka, Ken Kamata, Masatoshi Kudo

Summary: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a useful method for diagnosing pancreatic masses. The diagnostic performance of EUS-FNA can be improved by using contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS), which helps avoid fibrosis in the pancreatic mass. However, the effectiveness of CH-EUS-FNA is still a matter of debate, as only one out of eight studies showed improved sensitivity.

DIAGNOSTICS (2023)

Add to Collection

Article Medicine, General & Internal

Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease

Takushi Manabe, Chikara Ogawa, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Mitsushige Shibatoge, Asahiro Morishita, Masatoshi Kudo, Tsutomu Masaki

Summary: This study validated the assessment of sarcopenia using psoas muscle volume as a measure and found that sarcopenia was associated with shorter survival in patients with liver disease. The psoas muscle volume index (PMVI) may be useful in evaluating sarcopenia, including cases where sarcopenia cannot be diagnosed using the commonly used psoas muscle index (PMI).

DIAGNOSTICS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Oral administration of ovalbumin protects mice from concanavalin A-induced hepatitis through suppression of interferon-gamma responses

Tomohiro Watanabe, Kosuke Minaga, Hajime Honjo, Masatoshi Kudo

Summary: The liver showed hypo-responsiveness to antigens and high doses of orally-administered ovalbumin (OVA) generated unique CD4+ T cells and tolerogenic dendritic cells that can suppress Th1 responses. OVA administration at high doses inhibited hepatitis development in mice with OVA-specific CD4+ T cells, and this was associated with downregulation of Th1 responses. The results suggest that high-dose oral antigen administration can suppress Th1-mediated hepatitis in an antigen-non-specific manner.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014-2015)

Hiroko Iijima, Masatoshi Kudo, Shoji Kubo, Masayuki Kurosaki, Michiie Sakamoto, Shuichiro Shiina, Ryosuke Tateishi, Nakashima Osamu, Takumi Fukumoto, Yutaka Matsuyama, Takamichi Murakami, Arata Takahashi, Hiroaki Miyata, Norihiro Kokudo

Summary: Data from a nationwide follow-up survey of primary liver cancer in Japan, which compiled information from 20,889 newly registered patients and 42,274 previously registered follow-up patients, showed that patients with hepatocellular carcinoma (HCC) in the 23rd survey were older at the time of clinical diagnosis, had more female patients, had more non-B non-C HCC patients, had smaller tumor diameter, and were more frequently treated with hepatectomy compared to the previous survey. The data obtained from this survey are expected to contribute to advancing clinical research and treatment of primary liver cancer worldwide.

HEPATOLOGY RESEARCH (2023)

Add to Collection

Review Oncology

Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma

Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, Masatoshi Kudo

Summary: Thermal ablation therapy, including RFA and MWA, is a widely used treatment for hepatocellular carcinomas. It achieves good outcomes with minimal invasiveness. Successful thermal ablation therapy requires understanding the principles and characteristics of the treatment, assessing the benefits and risks, precise needle control and visualization, utilizing imaging guidance techniques, and evaluating therapeutic response. This overview provides essential information for the clinical application of thermal ablation.

CANCERS (2023)

Add to Collection

Article Oncology

Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update

Masatoshi Kudo

LIVER CANCER (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.